Leah Kleinman

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Depressive Symptoms

Top Venues

Pharmaceutical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Andrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, Dalma Seboek Kinter, Bruno Flamion
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials. Pharmaceutical medicine 38 (2) (2024)
Andrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, Dalma Seboek Kinter, Bruno Flamion
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials. Pharmaceutical medicine 38 (2) (2024)
Andrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, Dalma Seboek Kinter, Bruno Flamion
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials. Pharmaceutical medicine 38 (2) (2024)
Andrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, Dalma Seboek Kinter, Bruno Flamion
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials. Pharmaceutical medicine (2024)
Andrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, Dalma Seboek Kinter, Bruno Flamion
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials. Pharmaceutical medicine 38 (2) (2024)
Andrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, Dalma Seboek Kinter
Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant. Pharmaceutical medicine (2023)